Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SRC | P12931 | 5/20 | 0.52 |
| ▸ | ADK | P55263 | 9/20 | 0.51 |
| ▸ | EGFR | P00533 | 6/20 | 0.50 |
| ▸ | ABL1 | P00519 | 4/20 | 0.50 |
| ▸ | ABL2 | P42684 | 4/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.48 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655729 | 0.84 | ADK (0.48) | MTORRAB9ASRCADKEGFR | |
| SCHEMBL16654597 | 0.84 | SRC (0.52) | MTORRAB9ASRCADKEGFR | |
| SCHEMBL1441902 | 0.83 | MTOR (0.57) | MTORRAB9ASRCADKEGFR | |
| SCHEMBL16237288 | 0.83 | SRC (0.59) | MTORRAB9ASRCADKEGFR | |
| SCHEMBL30155310 | 0.80 | ABL1 (0.64) | MTORRAB9ASRCADKEGFR | |
| SCHEMBL400626 | 0.80 | SRC (0.61) | MTORRAB9ASRCADKEGFR | |
| SCHEMBL1940882 | 0.80 | ABL1 (0.64) | MTORRAB9ASRCADKEGFR | |
| SCHEMBL29484468 | 0.80 | SRC (0.61) | MTORRAB9ASRCADKEGFR | |
| SCHEMBL24650661 | 0.79 | MTOR (0.55) | MTORRAB9ASRCADKEGFR | |
| SCHEMBL17818397 | 0.79 | ABL1 (0.63) | MTORRAB9ASRCADKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | MTOR 27/4885RAB9A 886/4885SRC 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.